摘要
慢性乙型肝炎病毒(HBV)感染仍然威胁着人类健康,目前有效抗HBV药为干扰素类及核苷(酸)类,但以这两种药物为基础的治疗方案很难实现HBV感染彻底治愈,且临床治愈率有限。新型抗病毒药物的研发迫在眉睫。随着对HBV复制周期的深入认识,人们对HBV与肝细胞作用的不同靶点及免疫调节有了更深的了解。新型抗病毒药物主要针对HBV复制过程的不同环节及相关的免疫调节等方面,本文就新型抗HBV药物研发进展进行综述。
Chronic HBV infection is still a disease threatening human health.At present,the effective antiviral drugs include interferon and nucleos(t)ide analogues.However,it is still difficult to achieve a complete cure of HBV based on these two drugs,and the clinical cure rate is limited.The development of new anti-viral drugs is urgent.With the further understanding of HBV replication cycle,we have a deeper comprehension of the different targets and immune regulation of interaction between HBV and hepatocytes. New antiviral drugs are mainly aimed at different aspects of HBV replication and related immunomodulation. This paper reviews the progress of new anti-viral drugs.
作者
张珊
孙静
邢卉春
Zhang Shan;Sun Jing;Xing Huichun(Division 3rd of Centerof Hepatology,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China)
出处
《中华实验和临床感染病杂志（电子版）》
CAS
2019年第1期6-11,共6页
Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)
基金
北京市医院管理局扬帆计划(No.xmlx201837)
"十三五"艾滋病和病毒性肝炎等重大传染病防治(No.2018ZX10302206-003-006)
吴阶平医学基金会(No.LDWJPMF-103-17001)
关键词
肝炎
乙型
慢性
新型抗病毒药物
治疗
免疫调节
Hepatitis B virus
Chronic hepatitis B
New anti-HBV drugs
treatment
Immune modulators
